PT - JOURNAL ARTICLE AU - Hoffmann, Markus AU - Poschenrieder, Julian M. AU - Incudini, Massimiliano AU - Baier, Sylvie AU - Fitz, Amelie AU - Maier, Andreas AU - Hartung, Michael AU - Hoffmann, Christian AU - Trummer, Nico AU - Adamowicz, Klaudia AU - Picciani, Mario AU - Scheibling, Evelyn AU - Harl, Maximilian V. AU - Lesch, Ingmar AU - Frey, Hunor AU - Kayser, Simon AU - Wissenberg, Paul AU - Schwartz, Leon AU - Hafner, Leon AU - Acharya, Aakriti AU - Hackl, Lena AU - Grabert, Gordon AU - Lee, Sung-Gwon AU - Cho, Gyuhyeok AU - Cloward, Matthew AU - Jankowski, Jakub AU - Lee, Hye Kyung AU - Tsoy, Olga AU - Wenke, Nina AU - Pedersen, Anders Gorm AU - Bønnelykke, Klaus AU - Mandarino, Antonio AU - Melograna, Federico AU - Schulz, Laura AU - Climente-Gonzalez, Héctor AU - Wilhelm, Mathias AU - Iapichino, Luigi AU - Wienbrandt, Lars AU - Ellinghaus, David AU - Van Steen, Kristel AU - Grossi, Michele AU - Furth, Priscilla A. AU - Hennighausen, Lothar AU - Di Pierro, Alessandra AU - Baumbach, Jan AU - Kacprowski, Tim AU - List, Markus AU - Blumenthal, David B. TI - Network medicine-based epistasis detection in complex diseases: ready for quantum computing AID - 10.1101/2023.11.07.23298205 DP - 2023 Jan 01 TA - medRxiv PG - 2023.11.07.23298205 4099 - http://medrxiv.org/content/early/2023/11/09/2023.11.07.23298205.short 4100 - http://medrxiv.org/content/early/2023/11/09/2023.11.07.23298205.full AB - Most heritable diseases are polygenic. To comprehend the underlying genetic architecture, it is crucial to discover the clinically relevant epistatic interactions (EIs) between genomic single nucleotide polymorphisms (SNPs)1–3. Existing statistical computational methods for EI detection are mostly limited to pairs of SNPs due to the combinatorial explosion of higher-order EIs. With NeEDL (network-based epistasis detection via local search), we leverage network medicine to inform the selection of EIs that are an order of magnitude more statistically significant compared to existing tools and consist, on average, of five SNPs. We further show that this computationally demanding task can be substantially accelerated once quantum computing hardware becomes available. We apply NeEDL to eight different diseases and discover genes (affected by EIs of SNPs) that are partly known to affect the disease, additionally, these results are reproducible across independent cohorts. EIs for these eight diseases can be interactively explored in the Epistasis Disease Atlas (https://epistasis-disease-atlas.com). In summary, NeEDL is the first application that demonstrates the potential of seamlessly integrated quantum computing techniques to accelerate biomedical research. Our network medicine approach detects higher-order EIs with unprecedented statistical and biological evidence, yielding unique insights into polygenic diseases and providing a basis for the development of improved risk scores and combination therapies.Competing Interest StatementDuring the course of the project, HCG became a full-time employee of Novo Nordisk Ltd.Funding StatementThis work was supported in part by the Technical University Munich Institute for Advanced Study, funded by the German Excellence Initiative. This work was supported in part by the Intramural Research Programs (IRPs) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). MG is supported by CERN through the CERN Quantum Technology Initiative. AMA is supported by Foundation for Polish Science (FNP), IRAP project ICTQT, contract no. 2018/MAB/5, co-financed by EU Smart Growth Operational Programme. This work was supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the *e:Med* research and funding concept (*grants 01ZX1908A / 01ZX2208A* and *grants 01ZX1910D / 01ZX2210D*). This project has received funding from the European Unions Horizon 2020 research and innovation programme under grant agreement No 777111. This publication reflects only the authors' view and the European Commission is not responsible for any use that may be made of the information it contains. Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) grant number: 422216132. The research of LI and LSCHU is partially funded by the Bavarian State Ministry of Science and the Arts as part of the Munich Quantum Valley.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe LOAD data set is restricted and can be found at https://www.tgen.org. The users need to apply for the data set. The BD (EGAD00000000003), CAD (EGAD00000000004), T1D (EGAD00000000008), T2D (EGAD00000000009), HT (EGAD00000000006), IBD (EGAD00000000005), RA (EGAD00000000007), and the British 1958 British Birth Cohort (EGAD00000000001) data sets are restricted and can be found at https://www.sanger.ac.uk/legal/DAA/MasterController https://edam.sanger.ac.uk/#/. The user needs to apply for the data sets. In the future, we plan to include the following datasets in the Epistasis Disease Atlas: AS (EGAD00000000010), ATD (EGAD00000000011), MS (EGAD00000000012), BRCA (EGAD00000000013), TB (EGAD00000000016), UC (EGAD00000000025), PD (EGAD00000000057), AK (EGAD00010000150), SP (EGAD00010000262), IS (EGAD00010000264), CD (EGAD00010000246); these data sets are restricted and can be found at https://www.sanger.ac.uk/legal/DAA/MasterController. The user needs to apply for the data sets. The datasets for replication are restricted and can be found at UK Biobank database (www.ukbiobank.ac.uk), project IDs 32683 and 54273. The results of NeEDL stored in the Epistasis Disease Atlas are freely available under the CC BY-NC 4.0 license. The source code of NeEDL, the quantum computing module, and the R Shiny App is freely available under the GPLv3 license at GitHub: https://github.com/biomedbigdata/NeEDL. All features of NeEDL are dockerized and available at Dockerhub: https://hub.docker.com/r/bigdatainbiomedicine/needl https://epistasis-disease-atlas.com/home